Sandra P. D'Angelo, MD
Sarcoma Medical Oncologist & Cellular Therapist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Meet Medical Oncologist Sandra D’Angelo
Video DetailsAbout Me
- Associate Attending Physician
I am a medical oncologist specializing in the care of soft tissue sarcomas and bone sarcomas, as well as Merkel cell carcinoma.
I work very closely with our multidisciplinary team of medical oncologists, surgeons, radiation oncologists, nurses, and patient support advocates to provide the best care and treatment for patients with these rare diseases. Our highly specialized team recognizes and appreciates the unique challenges that confront our patients, and we are all committed to addressing their needs. I partner with my patients and empower them while ensuring that they always get optimal care.
Read more
In my research, I am developing innovative ways to use immunotherapy to treat these cancers. I have designed and conducted numerous clinical trials of investigational therapies (drugs in development) that use the body’s immune system to attack multiple types of sarcoma. These include trials of immune checkpoint inhibitors, which “release the brakes” on the immune system, allowing it to fight tumors. Immune checkpoint inhibitors have been shown to be effective in the treatment of specific sarcomas, such as undifferentiated pleomorphic sarcoma, angiosarcoma, and dedifferentiated liposarcoma. I have also led clinical trials studying T cells engineered to recognize a specific molecule on synovial sarcomas and myloid round cell liposarcomas.
In my translational research (research done in the laboratory to develop new ways to diagnose and treat disease), I am investigating biomarkers predictive of benefit from systemic immunotherapy in patients with sarcoma. At MSK, we are at the forefront of sarcoma immunotherapy research and have already contributed to the field in meaningful ways while improving the lives of our patients.
A sarcoma medical oncologist is a cancer doctor who specializes in sarcoma. This includes soft tissue sarcomas (such as Ewing sarcoma and rhabdomyosarcoma) and benign (not cancer) growths that are like sarcoma.
A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.
My Specialties
- Sarcomas of Soft Tissue and Bone
- Merkel Cell Carcinoma
Education
- MD, SUNY Downstate College of Medicine
Residencies
- Internal Medicine - New York University
- Internal Medicine - Memorial Sloan Kettering Cancer Center
- Chief Residency (Internal Medicine) - Memorial Sloan Kettering Cancer Center
Awards and Honors
- R01 CA259169-01A1, FDA (2022)
- P50 CA217694 Career Enhancement Award (2020)
- Sarcoma Foundation Alliance (2018)
- Research Grant Recipient, Memorial Sloan Kettering Cancer Center Society (2015)
- Career Development Award, Conquer Cancer, the ASCO Foundation (2015)
- Alliance Scholar Award, Alliance for Clinical Trials in Oncology Foundation (2014)
- Young Investigator Award, Conquer Cancer, the ASCO Foundation (2011)
Fellowships
- Oncology - Memorial Sloan Kettering Cancer Center
Board Certifications
- Internal Medicine
- Medical Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. D'Angelo sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. D'Angelo
- A Phase II Study of ADP-A2M4 Gene Therapy in People with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
- Clinical Trials Co-Investigated by Dr. D'Angelo
- A Phase 1 Study of CRD3874-SI in People With Advanced Sarcoma or Merkel Cell Cancer
- A Phase 1a/2 Study of GI-102 Immunotherapy in People With Advanced Sarcoma
- A Phase II Study of Pembrolizumab Immunotherapy plus Local Chemotherapy using Isolated Limb Infusion for Patients with Advanced Sarcoma in the Arm or Leg
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
D’Angelo SP, Melchiori L, Merchant MS, Bernstein D, Glod J, Kaplan R, Grupp S, Tap WD, Chagin K, Binder GK, Basu S, Lowther DE, Wang R, Bath N, Tipping A, Betts G, Ramachandran I, Navenot JM, Zhang H, Wells DK, Van Winkle E, Kari G, Trivedi T, Holdich T, Pandite L, Amado R, Mackall CL. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. Cancer Discov. 2018 Aug;8(8):944-957. doi: 10.1158/2159-8290.CD-17-1417. Epub 2018 Jun 11. PMID: 29891538; PMCID: PMC8092079.
D’Angelo SP, Mahoney MR, Van Tine BA, Atkins J, Milhem MM, Jahagirdar BN, Antonescu CR, Horvath E, Tap WD, Schwartz GK, Streicher H. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol. 2018 Mar;19(3):416-426. doi: 10.1016/S1470-2045(18)30006-8. Epub 2018 Jan 19. PMID: 29370992; PMCID: PMC6126546.
Read more
D’Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, Kelly C, Keohan ML, Movva S, Thornton K, Rosenbaum E, Chi P, Nacev B, Chan JE, Slotkin EK, Kiesler H, Adamson T, Ling L, Rao P, Patel S, Livingston JA, Singer S, Agaram NP, Antonescu CR, Koff A, Erinjeri JP, Hwang S, Qin LX, Donoghue MTA, Tap WD. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022 Jun 16;13(1):3477. doi: 10.1038/s41467-022-30874-8. PMID: 35710741; PMCID: PMC9203519.
D’Angelo SP, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Prinzi N, Hanna GJ, Hassel JC, Kiecker F, Georges S, Ellers-Lenz B, Shah P, Güzel G, Nghiem P. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021 Jul;9(7):e002646. doi: 10.1136/jitc-2021-002646. PMID: 34301810; PMCID: PMC8311489.
Rosenbaum E, Antonescu CR, Smith S, Bradic M, Kashani D, Richards AL, Donoghue M, Kelly CM, Nacev B, Chan JE, Chi P, Dickson MA, Keohan ML, Gounder MM, Movva S, Avutu V, Thornton K, Zehir A, Bowman AS, Singer S, Tap W, D’Angelo S. Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center. J Immunother Cancer. 2022 Apr;10(4):e004149. doi: 10.1136/jitc-2021-004149. PMID: 35365586; PMCID: PMC8977792.
Visit PubMed for a full listing of Dr. D'Angelo’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Sandra P. D'Angelo discloses the following relationships and financial interests:
-
Adaptimmune
Professional Services and Activities -
GI Innovation Inc.
Professional Services and Activities -
Incyte
Professional Services and Activities
-
Medendi
Professional Services and Activities -
Piper Sandler & Co.
Professional Services and Activities
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].